Type Condition

Cleveland, OH

207 Clinical Paid Trials near Cleveland, OH

Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Viral Therapy + Pembrolizumab for Head and Neck Cancer

Cleveland, Ohio
This trial is testing two new drugs, HB-201 and HB-202, which aim to help the immune system fight HPV 16-related cancers. It focuses on patients with advanced head and neck cancer who are also receiving a standard treatment called pembrolizumab. The goal is to see if these new drugs can improve the body's ability to combat cancer.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

200 Participants Needed

IMGN632 + Venetoclax/Azacitidine for Acute Myeloid Leukemia

Cleveland, Ohio
This trial tests a new drug, IMGN632, combined with other drugs to treat patients with a specific type of leukemia. It aims to see if this combination can effectively target and kill cancer cells while stopping them from growing.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

218 Participants Needed

Niraparib + Standard Therapy for Prostate Cancer

Cleveland, Ohio
This is a phase I-II trial to find the safety and activity of adding a new drug (neraparib) to the usual treatment (radiation combined with male hormone deprivation therapy) in lowering the chance of prostate cancer growing or returning. Niraparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Adding niraparib to the usual care may lower the chance of prostate cancer growing or returning.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Sex:Male

22 Participants Needed

Telaglenastat + Osimertinib for Non-Small Cell Lung Cancer

Cleveland, Ohio
This phase Ib trial studies the side effects and best dose of telaglenastat hydrochloride when given together with osimertinib in treating patients with stage IV non-small cell lung cancer and a mutation in the EGFR gene. Telaglenastat hydrochloride and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

23 Participants Needed

T Cell-Depleted Stem Cell Transplant for Leukemia

Cleveland, Ohio
This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant. Sometimes the transplanted white blood cells from a donor attack the body's normal tissues (called graft versus host disease). Removing a particular type of T cell (naive T cells) from the donor cells before the transplant may stop this from happening.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:6 - 26

68 Participants Needed

Combination Immunotherapy + VSV-IFNβ-NIS for Solid Tumors

Cleveland, Ohio
This trial tests a combination of a virus-based therapy and an immune-boosting drug for patients with hard-to-treat cancers. The treatment works by making cancer cells more visible to the immune system and keeping the immune system active against them.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

86 Participants Needed

Glycine Buffer for Airway pH Measurement in Asthma

Cleveland, Ohio
This study is testing a non invasive way to measure airway pH in individuals with Asthma and Cystic Fibrosis using a new inhaled drug. The airway pH will help health care providers in creating tailored treatment plans for individuals suffering from these specific conditions.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 50

74 Participants Needed

MCLA-158 for Solid Cancers

Cleveland, Ohio
This trial is testing a new drug called MCLA-158 to see if it can help treat certain cancers by blocking a protein that helps cancer cells grow. It focuses on patients with cancers that rely on this protein, like colorectal and head and neck cancers.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

523 Participants Needed

Ivosidenib + Venetoclax +/- Azacitidine for Leukemia

Cleveland, Ohio
This phase Ib/II trial studies the side effects and best dose of venetoclax and how well it works when given together with ivosidenib with or without azacitidine, in treating patients with IDH1-mutated hematologic malignancies. Venetoclax and ivosidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ivosidenib and venetoclax with azacitidine may work better in treating patients with hematologic malignancies compared to ivosidenib and venetoclax alone.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

96 Participants Needed

CAB-AXL-ADC + PD-1 Inhibitor for Sarcoma

Cleveland, Ohio
This trial is testing mecbotamab vedotin, a medicine that targets and kills cancer cells, in patients with advanced solid tumors, including specific types of sarcomas. It works by using an antibody to find the cancer cells and a drug to destroy them.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:12+

300 Participants Needed

JCAR017 for Chronic Leukemia or Lymphoma

Cleveland, Ohio
This trial tests JCAR017, a therapy using modified immune cells, in adults with hard-to-treat CLL or SLL. It aims to see if these enhanced immune cells can better fight the cancer.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

320 Participants Needed

LITT + Pembrolizumab for Glioblastoma

Cleveland, Ohio
The purpose of this study is to test the side effects and efficacy of using Laser Interstitial Thermotherapy (LITT) combined with Pembrolizumab. LITT is a minimally invasive surgical technique that uses a laser to heat brain tumors. Pembrolizumab is an investigational (experimental) drug that works by helping participants' immune system work correctly to detect and fight cancer cells. Pembrolizumab is experimental because it is not approved by the Food and Drug Administration (FDA), for this use, though it is approved to treat other cancers.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

34 Participants Needed

Inotuzumab Ozogamicin Post-Transplant for Leukemia and Lymphoma

Cleveland, Ohio
This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects without having too many side effects. The Phase II portion of this study is to see what side effects are seen with medication after transplant. Inotuzumab ozogamicin is a combination of an antibody and chemotherapy which has been shown to have significant activity against relapsed/refractory acute lymphocytic leukemia (ALL). Inotuzumab ozogamicin is considered experimental in this study.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:16 - 75

44 Participants Needed

Chemotherapy with Bortezomib + Vorinostat for Acute Lymphoblastic Leukemia

Cleveland, Ohio
The purpose of this study is to test the good and bad effects of the study drugs bortezomib and vorinostat when they are given in combination with chemotherapy commonly used to treat acute lymphoblastic leukemia (ALL) in infants. For example, adding these drugs could decrease the number of leukemia cells, but it could also cause additional side effects. Bortezomib and vorinostat have been approved by the US Food and Drug Administration (FDA) to treat other cancers in adults, but they have not been approved for treating children with leukemia. With this research, we plan to meet the following goals: PRIMARY OBJECTIVE: * Determine the tolerability of incorporating bortezomib and vorinostat into an ALL chemotherapy backbone for newly diagnosed infants with ALL. SECONDARY OBJECTIVES: * Estimate the event-free survival and overall survival of infants with ALL who are treated with bortezomib and vorinostat in combination with an ALL chemotherapy backbone. * Measure minimal residual disease (MRD) positivity using both flow cytometry and PCR. * Compare end of induction, end of consolidation, and end of reinduction MRD levels to Interfant99 (ClinicalTrials.gov registration ID number NCT00015873) participant outcomes.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:All

50 Participants Needed

BCG + N-803 for Bladder Cancer

Cleveland, Ohio
This is a Phase Ib/IIb, randomized, two-cohort, open-label, multicenter study of intravesical N-803 plus BCG versus BCG alone, in BCG naïve patients with high-grade NMIBC.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

596 Participants Needed

Brentuximab Vedotin + Nivolumab ± Ipilimumab for Hodgkin's Lymphoma

Cleveland, Ohio
This phase I/II trial studies the side effects and best dose of ipilimumab and nivolumab when given together with brentuximab vedotin, and how well they work in treating patients with Hodgkin lymphoma that has returned after a period of improvement (recurrent) or has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. It is not known whether giving brentuximab vedotin and nivolumab with or without ipilimumab may kill more cancer cells.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:12+

146 Participants Needed

Radiosurgery for Brain Tumor

Cleveland, Ohio
This Phase I/II trial studies the ability to stop brain metastases from coming back after treatment with radiosurgery followed by surgical resection. It will also evaluate the side effects of these combined treatments and help determine the best radiosurgery dose. Radiosurgery focuses the x-rays directly to the tumor and cause less damage to the normal tissue in the brain.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

36 Participants Needed

AVZO-023 for Breast Cancer

Cleveland, Ohio
This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in patients with advanced solid tumors. AVZO-023 is an oral medication that inhibits cyclin-dependent kinase 4 (CDK4).
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 1, 2

380 Participants Needed

JAB-23E73 for Cancer

Cleveland, Ohio
This study is to evaluate the safety and tolerability of JAB-23E73 in adult participants with advanced solid tumors
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 1, 2

294 Participants Needed

ZL-1310 for Cancer

Cleveland, Ohio
A Phase Ib/II, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

86 Participants Needed

Why Other Patients Applied

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

CGT4859 for Bile Duct Cancer

Cleveland, Ohio
This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult participants with intrahepatic cholangiocarcinoma (iCCA) or other advanced solid tumors with FGFR2 and/or FGFR3 genetic alternations.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

110 Participants Needed

TUB-030 for Cancer

Cleveland, Ohio
The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 as a single drug given to patients with solid cancer Researchers will also compare doses of TUB-030 in two specific cancer types, in patients with head and neck cancer and patients with non-small cell lung cancer, to see if TUB-030 works to treat these two solid cancer types and to determine the best dose. Participants will: Receive drug TUB-030 every 3 weeks Visit the clinic once every 3 weeks for checkups and tests Answer patient reported outcome questionnaires about their symptoms
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

130 Participants Needed

BMS-986507 Combinations for Lung Cancer

Cleveland, Ohio
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

198 Participants Needed

BC3402 + Tremelimumab + Durvalumab for Liver Cancer

Cleveland, Ohio
The purpose of this study is to test the safety and efficacy of an investigational (experimental) product called BC3402. This product is considered experimental because it is not approved by the U.S. Food and Drug Administration (FDA).
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 1, 2

43 Participants Needed

SBRT + Pluvicto for Prostate Cancer

Cleveland, Ohio
The goal of this clinical trial is to is to investigate if it is possible to lower the chance of cancer reoccurrence and also preserve quality of life by using the drug Pluvicto instead of androgen-deprivation therapy to the usual radiation therapy for advanced local prostate cancer. Participants will receive one dose of Pluvicto, followed by radiation about 6 weeks later. Radiation therapy will be completed in 5 treatments over the period of 2 weeks. A second dose of Pluvicto will be given 6 weeks after radiation is complete. Some participants may also receive a third dose of Pluvicto, and this would be given 6 weeks after the second dose of Pluvicto.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Sex:Male

45 Participants Needed

Sacituzumab + Enfortumab With/Without Pembrolizumab for Bladder Cancer

Cleveland, Ohio
This study is a substudy being conducted under one pembrolizumab umbrella master study KEYMAKER-U04. The substudy will consist of 2 parts. Part 1 will evaluate the safety and preliminary efficacy of sacituzumab tirumotecan plus enfortumab vedotin (EV). Part 2 will be based on Part 1 results and will evaluate the efficacy, pharmacokinetics, and safety of sacituzumab tirumotecan plus EV in combination with pembrolizumab in participants with advanced urothelial carcinoma.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

98 Participants Needed

Prehabilitation for Ovarian and Pancreatic Cancer

Cleveland, Ohio
The purpose of this study is to see whether participants who are assigned to a multimodal prehabilitation intervention during chemotherapy are able to adhere with exercise and nutrition program to prepare for their cancer surgery.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:65+

22 Participants Needed

JAB-30355 for Solid Tumors

Cleveland, Ohio
This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

144 Participants Needed

Amivantamab Combinations for Head and Neck Cancer

Cleveland, Ohio
This trial is testing a new drug called amivantamab alone and with two other drugs, pembrolizumab and paclitaxel. It targets patients with head and neck cancer that has come back or spread. Amivantamab blocks signals that help cancer grow, pembrolizumab helps the immune system fight cancer, and paclitaxel stops cancer cells from dividing. Pembrolizumab has shown benefits when used with chemotherapy.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

247 Participants Needed

Opevesostat-Based Treatments for Prostate Cancer

Cleveland, Ohio
Substudy 01A is part of a larger research study that is testing experimental treatments for metastatic castration-resistant prostate cancer (mCRPC). The larger study is the umbrella study (U01). The goal of substudy 01A is to evaluate the safety and efficacy of opevesostat-based treatment combinations, or as a single agent, in participants with mCRPC. This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for the opevesostat-based treatment combinations. There will be no hypothesis testing in this study.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

220 Participants Needed

1234...7

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do clinical trials in Cleveland, OH pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do clinical trials in Cleveland, OH work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Cleveland, OH 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Cleveland, OH is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Cleveland, OH several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a medical study in Cleveland, OH?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest clinical trials in Cleveland, OH?

Most recently, we added Vision Therapy for Convergence Insufficiency, BC3402 + Tremelimumab + Durvalumab for Liver Cancer and MRF-Guided Surgery for Brain Tumors to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials in Ohio

Anxiety Clinical Trials in Ohio

Schizophrenia Clinical Trials in Ohio

ADHD Clinical Trials in Ohio

Bipolar Disorder Clinical Trials in Ohio

Multiple Sclerosis Clinical Trials in Ohio

Autism Clinical Trials in Ohio

Treatment Resistant Depression Clinical Trials in Ohio

Borderline Personality Disorder Clinical Trials in Ohio

Social Anxiety Disorder Clinical Trials in Ohio

Parkinson's Disease Clinical Trials in Ohio

Alzheimer's Disease Clinical Trials in Ohio

By Location

Clinical Trials near Cleveland, OH

Clinical Trials near Columbus, OH

Clinical Trials near Cincinnati, OH

Clinical Trials near Dayton, OH

Clinical Trials near Toledo, OH

Clinical Trials near Akron, OH

Clinical Trials near Canton, OH

Clinical Trials near Kettering, OH

Clinical Trials near Findlay, OH

Clinical Trials near Franklin, OH

Clinical Trials near Delaware, OH

Clinical Trials near Springfield, OH

Other People Viewed

By Subject

40 Depression Trials near Cleveland, OH

20 Bipolar Disorder Trials near Cleveland, OH

Top Clinical Trials near Cleveland, OH

36 Alzheimer's Disease Trials near Cleveland, OH

157 Clinical Trials near Beachwood, OH

39 Hypertension Trials near Akron, OH

Top Clinical Trials near Fairfield, OH

Top Clinical Trials near Cincinatti, OH

Top Clinical Trials near Canfield, OH

Top Clinical Trials near Clyde, OH

Top Clinical Trials near Bexley, OH

Top Clinical Trials near Alliance, OH

By Trial

Sodium Hyaluronate for Non-Alcoholic Fatty Liver Disease

Electrical Stimulation for Learning and Memory in Alzheimer's and Primary Progressive Aphasia

Suicide Prevention Interventions for Suicide Risk Management

Blood Pressure Management During Surgery for High Blood Pressure

Tendon Transfer Techniques for Rotator Cuff Tears

Maternal Enteroviral Infection and Diabetes Impact on Congenital Heart Defects

Genomic Analysis for Hereditary Cancer

Celecoxib for Chronic Rhinosinusitis

Intermittent CGM Use for Prediabetes

CD22 CAR T Cell Therapy for Hairy Cell Leukemia

Pembrolizumab for Lymphoma

mHealth App for Gambling Addiction

Related Searches

Top Lung-cancer Clinical Trials

Antibiotics for Pediatric Broken Bones

Lifestyle Interventions for Gestational Diabetes

Combined Ablation Techniques for Ventricular Tachycardia

Niraparib + TSR-042 for Endometrial Cancer

Digital Self-Management for Childhood Cancer Survivors

Pre-Surgery Radiation Therapy for Breast Cancer

Barzolvolimab for Eosinophilic Esophagitis

Stepped Care Suicide Prevention for Youth

Top Trauma Clinical Trials

Gene Therapy for Duchenne Muscular Dystrophy

RUBI Program for Autism Spectrum Disorder

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial